Oct 30 (Reuters) - Halozyme Therapeutics Inc:
* HALOZYME LICENSES NEW ENHANZE TARGETS FOR $25 MILLION UPFRONT PAYMENT, FUTURE MILESTONES AND ROYALTIES
* HALOZYME THERAPEUTICS-LICENSED ENHANZEDRUG-DELIVERY TECHNOLOGY TO ROCHE FOR EXCLUSIVE DEVELOPMENT OF NEW UNDISCLOSED CLINICAL STAGE THERAPEUTIC TARGET
* HALOZYME - IN DEAL, CO TO RECEIVE UPFRONT FEE OF $25 MILLION WITH POTENTIAL TO EARN ADDITIONAL PAYMENTS OF UP TO $160 MILLION TO $165 MILLION PER TARGET
* HALOZYME THERAPEUTICS INC - COMPANY EXPECTS TO RECOGNIZE INITIAL $25 MILLION PAYMENT IN Q4 OF 2018.
* HALOZYME THERAPEUTICS INC - ALSO HALOZYME WILL RECEIVE A NOMINATION FEE FOR EACH OF TWO ADDITIONAL NEW TARGET NOMINATIONS
* HALOZYME THERAPEUTICS INC - HALOZYME WILL ALSO RECEIVE MID-SINGLE DIGIT ROYALTIES ON SALES OF COMMERCIALIZED PRODUCTS Source text for Eikon: Further company coverage: